興證國際(06058.HK):於公開市場購買本金總額685.5萬美元票據
格隆匯5月22日丨興證國際(06058.HK)發佈公吿,公司間接全資附屬公司CISI Investment自2024年5月7日至5月21日期間,於公開市場購買本金總額為685.5萬美元(相當於約5381.2萬港元)的票據,總代價為約681.97萬美元(相當於約5353.5萬港元)。該票據為由日本生命保險相互會社發行的於2046年到期的本金總額為15億美元年息4.70%以美元計價的次級票據。
根據披露,發行人為日本互助公司,其為日本人壽集團的核心公司,該集團由在亞太地區及全球經營人壽保險和資產管理業務的多家集團公司組成,是日本最大的私人資產所有者。發行人作為保險公司運營,提供疾病、住院、護理、死亡、退休金、教育和其他人壽保險服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.